Kaposi's Sarcoma (KS) is the most common tumor associated with HIV infection. KS represents a vascular proliferation characterized by multiple lesions at initial presentation. an identical tumor develops in other settings without HIV infection, including the classic form seen predominantly in older Eastern European men, an African form, renal transplant recipients, and iatrogenically induced by glucocorticoids disease. Clinically, KS is a heterogeneous course that appears to be independent of the severity of immunodeficiency. KS in highly vascular angiogenic tumor that appears to be of endothelial cell origin. Gill's group has demonstrated in the past that angiogenic factors bFGF, VEGF and IL8 and inducers of angiogenesis IL6, TGFbeta, IL1beta and TNFalpha are all expressed in KS cells and more recently that VEGF is an autocrine factor, a permeability factor and a survival factor for KS cells in culture. He has also found that all known members of the VEGF family and VEGF-R family are expressed in both KS cell lines and KSHV infected EC cultures. He proposes that VEGF is the critical growth factor for KS and that VEGF/VEGF-R proteins represent the convergence points for all KS growth factor cascades. Therefore, he proposes to both demonstrate this and define the roles of individual VEGF/VEGF- R family members in both the KS Y-1 spindle cell line and in the recently developed KSHV infected BMEC system of Flore et al, as well as confirm expression of all of these proteins in primary KS tumor tissue. A comprehensive set of experiments focused on the following three Specific Aims are proposed.
Specific Aim 1 is designed to use specific reagents to define and compare the expression and roles of VEGF-A, VEGF-B, VEGF-C, VEGF-D and PIGF, including the use of antisense phosphorothioate oligonucleotide inhibitors and VEGF-R antibodies to examine effects on cell proliferation, migration and survival. The new Specific Aim 2 involves an investigation of the importance of the greatly increased constitutive levels of ERK activation (an apparent downstream VEGF effect) found in KS cells compared to normal HUVEC or skin cells. Whether this is needed for cell survival and whether KSHV infection also induces ERK activation as a appropriate critical event will be examined as well as pharmacological intervention at other stages of MAPK signal transduction.
New Specific Aim 3 represents an attempt to establish the hierarchy and possible convergence of IL1beta and IL6 autocrine growth factor action in relation to VEGF survival signaling by individually blocking all three loops and studying the impact on cell growth, migration, apoptosis and second messenger activity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA079218-01A1
Application #
2873498
Study Section
Special Emphasis Panel (ZRG1-AARR-4 (01))
Program Officer
Finerty, John F
Project Start
1999-06-01
Project End
2004-03-31
Budget Start
1999-06-01
Budget End
2000-03-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Trindade, Alexandre; Djokovic, Dusan; Gigante, Joana et al. (2012) Low-dosage inhibition of Dll4 signaling promotes wound healing by inducing functional neo-angiogenesis. PLoS One 7:e29863
Liu, Ren; Trindade, Alexandre; Sun, Zhanfeng et al. (2012) Inhibition of Notch signaling by Dll4-Fc promotes reperfusion of acutely ischemic tissues. Biochem Biophys Res Commun 418:173-9
Liu, Ren; Gong, Ming; Li, Xiuqing et al. (2010) Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma. Blood 116:297-305
Liu, Ren; Li, Xiuqing; Tulpule, Anil et al. (2010) KSHV-induced notch components render endothelial and mural cell characteristics and cell survival. Blood 115:887-95
Djokovic, Dusan; Trindade, Alexandre; Gigante, Joana et al. (2010) Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer 10:641
Krasnoperov, Valery; Kumar, S Ram; Ley, Eric et al. (2010) Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. Am J Pathol 176:2029-38
He, Shikun; Kumar, S Ram; Zhou, Peng et al. (2010) Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro. Invest Ophthalmol Vis Sci 51:543-52
Spannuth, Whitney A; Mangala, Lingegowda S; Stone, Rebecca L et al. (2010) Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 9:2377-88
Kumar, S Ram; Scehnet, Jeffrey S; Ley, Eric J et al. (2009) Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res 69:3736-45
Scehnet, Jeffrey S; Ley, Eric J; Krasnoperov, Valery et al. (2009) The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 113:254-63

Showing the most recent 10 out of 23 publications